Markets:

Overview

News

Currencies

International

Treasuries

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

184.71 UNCHANGED

Last Price Updated: 4:00 PM EST, Dec 31, 2024 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about BeiGene, Ltd. - American Depositary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

The Latest Analyst Ratings for BeiGene ↗

September 12, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For September 12, 2023 ↗

September 12, 2023

Via Benzinga

Tesla, Crinetics Pharmaceuticals And Other Big Stocks Moving Higher In Monday's Pre-Market Session ↗

September 11, 2023

U.S. stock futures traded higher this morning on Monday. Here are some big stocks recording gains in today’s pre-market trading session.

Via Benzinga

Analyst Expectations for BeiGene's Future ↗

August 17, 2023

Via Benzinga

Why Are BeiGene Shares Trading Lower Today ↗

July 11, 2023

BeiGene Limited (NASDAQ: BGNE) shares are trading lower after the company mutually agreed to

Via Benzinga

What's Happening With Beigene Shares During Wednesday's Session ↗

June 21, 2023

Beigene Ltd (NASDAQ: BGNE) shares are trading lower by 3.41% to $185.03 Wednesday morning on downward momentum following Tuesday weakness.

Via Benzinga

Why Avantax Shares Are Trading Higher By Over 27%? Here Are Other Stocks Moving In Monday's Mid-Day Session ↗

September 11, 2023

Gainers Crinetics Pharmaceuticals, Inc. (NASDAQ: CRNX) jumped 76% to $28.13 after the company's once-daily oral paltusotine achieved the primary and secondary endpoints in the Phase 3 PATHFNDR-1 study...

Via Benzinga

PDD Holdings, UP Fintech Holding, Big Lots And Other Big Stocks Moving Higher On Tuesday ↗

August 29, 2023

U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Tuesday. Here are some big stocks recording gains in today’s session.

Via Benzinga

Topics Stocks

Recap: BeiGene Q1 Earnings ↗

May 04, 2023

Via Benzinga

BeiGene's Tislelizumab/Chemo Combo Hits Primary Goal In Gastric Cancer Study ↗

April 20, 2023

Via Benzinga

Verizon To Rally Around 20%? Here Are 10 Other Analyst Forecasts For Tuesday ↗

August 29, 2023

Stifel raised the price target for Hersha Hospitality Trust (NYSE: HT) from $8.75 to $10. Stifel analyst Simon Yarmak downgraded the stock from Buy to Hold. Hersha Hospitality Trust shares fell 0.5% to...

Via Benzinga

Who Are Other Players Gaining From Roche's Accidental Lung Cancer Data Update ↗

August 23, 2023

Earlier today, Roche Holdings AG (OTC: RHHBY) announced that it had been made aware of inadvertent disclosure of the second interim analysis of Phase 3 SKYSCRAPER-01 study, evaluating tiragolumab plus...

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For August 17, 2023 ↗

August 17, 2023

Via Benzinga

Week In Review: BeiGene And Bristol-Myers Squibb Close BeiGene-Celgene PD-1 Partnership ↗

August 12, 2023

BeiGene and Bristol-Myers Squibb have formally completed the breakup of the BeiGene-Celgene partnership, returning 23.3 million ordinary BeiGene shares to BeiGene. Meanwhile, Gracell Biotechnologies...

Via Talk Markets

Growing Competition in Hematology, Aesthetics Complicates AbbVie's Post-Humira Landscape, Analyst Says ↗

July 25, 2023

William Blair has initiated coverage on AbbVie Inc (NYSE: ABBV) with a

Via Benzinga

BeiGene's Brukinsa Positioned as Preferred BTK Inhibitor: Analyst Says Survey Supports Bullish View ↗

July 17, 2023

Citi initiated coverage on BeiGene Ltd (NASDAQ: BGNE) with a price target of $275 and a B

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For July 17, 2023 ↗

July 17, 2023

Via Benzinga

Benzinga's Top Ratings Upgrades, Downgrades For June 30, 2023 ↗

June 30, 2023

Via Benzinga

Why This BeiGene Analyst Slashes Forecast By Almost 42% ↗

June 30, 2023

BeiGene Ltd (NASDAQ: BGNE) declined in early trading on Friday, maintaining its downward trajectory through the week amid weakness in Chinese stocks.

Via Benzinga

NVIDIA To Rally Over 16%? Here Are 10 Other Analyst Forecasts For Friday ↗

June 30, 2023

Truist Securities boosted the price target for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) from $125 to $140. Truist Securities analyst Robyn Karnauskas maintained a Buy rating. BioMarin Pharmaceutical...

Via Benzinga

AbbVie Says BeiGene's Flagship Blood Cancer Drug Infringes Imbruvica Patent ↗

June 15, 2023

BeiGene Ltd (NASDAQ: BGNE) says it is aware that Pharmacyclics LLC has filed a complaint alleging that BeiGene's blood cancer therapy Brukinsa (zanubrutinib) infringes a Pharmacyclics

Via Benzinga

Why MicroVision Shares Are Trading Higher By 28%; Here Are 20 Stocks Moving Premarket ↗

June 15, 2023

Gainers EdtechX Holdings Acquisition Corp. II (NASDAQ: EDTX) shares gained 139.8% to $26.54 in pre-market trading.

Via Benzinga

Gambling.com, Editas Medicine And Other Big Stocks Moving Lower In Thursday's Pre-Market Session ↗

June 15, 2023

U.S. stock futures traded lower this morning. Here are some big stocks recording losses in today’s pre-market trading session.

Via Benzinga

Mirati's Sitravatinib Flunks Phase 3 Combo Therapy Study In Type Of Lung Cancer Setting ↗

May 25, 2023

Via Benzinga

Immix Biopharma's Subsidiary Says Investigational CAR T Therapy Shows 100% Response Rate In Amyloidosis ↗

May 22, 2023

Immix Biopharma Inc's (NASDAQ: IMMX) subsidiary Nexcella Inc announced updated AL Amyloidosis clinical data from its ongoing Phase 1b/2a NEXICART-1 study of its BCMA-targeted chimeric antigen receptor...

Via Benzinga

What's Going On With Immix Biopharma Stock Today ↗

May 03, 2023

Immix Biopharma Inc (NASDAQ: IMMX) announced early interim data from IMMINENT-01 Phase 1b/2a trial combining tissue-specific therapeutic IMX-110 with BeiGene Ltd (NYSE: BGNE) / Novartis AG'

Via Benzinga

3 Top Biotech Stocks Defying the Bear Market ↗

April 25, 2023

All three companies have therapies with strong sales potential.

Via The Motley Fool

7 Biotech Stocks That Could Cure Your Portfolio Woes ↗

April 19, 2023

If you want to revitalize your portfolio with some exciting opportunities, these biotech stocks to buy might fit the bill.

Via InvestorPlace

Analysts At H.C. Wainwright & Co. Set 12-Month Target Of $15 Per Share For ENLV Thanks To High Profile Collaboration Agreement, Multiple Ongoing Clinical Trials ↗

April 13, 2023

This month, H.C. Wainwright & Co.

Via Benzinga

Hillstream BioPharma's Drug Candidate HSB-1216 Could Be One To Watch As Global Oncology Market Continues To Grow ↗

April 11, 2023

A surge in oncology drug development, coupled with increased patient access and early diagnosis, has resulted in a massive increase in global spending on cancer treatments. Due to this, the global...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 10 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.

BeiGene, Ltd. - American Depositary Shares (NQ:BGNE)

Headline News about BeiGene, Ltd. - American Depositary Shares

Starting at $3.75/week.

Subscribe Today